MicroPort<sup>®</sup> NeuroTech Attends CSA&TISC to Promote APOLLO

Beijing, China – 3 July, 2015 - MicroPort NeuroTech (Shanghai) Co ("MicroPort® NeuroTech"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort®"), recently attended the First Academic Meeting of Chinese Stroke Association and 2015 Tiantan International Stroke Conference ("CSA&TISC") held from June 26 to June 28 in Beijing, to promote our neurovascular device APOLLO Intracranial Stent System ("APOLLO").
 
During the conference which attracted several thousand experienced surgeons, Professor Zhongrong Miao of Beijing Tian Tan Hospital issued a report named "Result and Prospect of Registry in Endovascular Treatment for Intracranial Arterial Stenosis in China" in which he released the research result of APOLLO Balloon-Mounted Stent for Symptomatic Intracranial Artery Stenosis Registry Study in China: The rate of 30-day primary safety end point is 4.4%, better than the result from the SAMMPRIS, in which the rate in stent group is 14.7% and that in medical group is 5.8%.
 
"APOLLO is equipped with a rapid-exchange design which allows precise positioning and excellent radial force," said Bo Peng, MicroPort® Chief Marketing Office and the Executive Director of MicroPort® NeuroTech. "Such clinical outcome also showed the excellent surgical skills of surgeons in the 12 famous neuro-medical centers represented by Beijing Tian Tan Hospital, which proves that China now leads the world in Intracranial stents surgeries."
 
Independently designed and developed by MicroPort®, APOLLO was launched in the China market in 2005. It is China's first intracranial vascular stent for the treatment of ischemic cerebrovascular disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009 and was listed in the National Key New Products Scheme in 2011.